Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02642237
Other study ID # LPS-Fluenz
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 2015
Est. completion date February 2018

Study information

Verified date May 2019
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the bacterial-viral interactions between LPS and Fluenz as a model for sepsis (bacterial) and Influenza (viral) infections which are common and associated with high mortality rates in the ICU. To understand these interactions is important for the development of preventive and therapeutic interventions.


Description:

The Influenza virus is known for its severe course of infection and systemic effects, associated with high mortality rates. Recent work has shown that influenza promotes susceptibility for secondary bacterial infections, thereby worsening the prognosis. While it has become clear that bacterial infections induce an immunosuppressed state in which the immune response against viral infections is attenuated1, it is unknown how a bacterial infection, such as in sepsis, influences the susceptibility and immune response to influenza. The sepsis-induced immunosuppressive state, called "immunoparalysis", may be a major contributor to this increased vulnerability. Because of the high mortality rates of both sepsis and influenza, it is of main importance to understand this interaction for the development of putative preventive and therapeutic interventions in ICU patients.

Human endotoxemia represents a model of systemic inflammation, mimicking bacterial sepsis and subsequent development of immunoparalysis. The live, attenuated, quadrivalent influenza vaccine "Fluenz™" is registered in the European Union and can be used as a surrogate for an actual influenza infection. In this study, we want to investigate the effects of an endotoxemia challenge on the Fluenz™-induced inflammatory response to present unique in vivo data on mechanistic interactions of systemic LPS followed by mucosal Fluenz™, thereby providing clues regarding the increased vulnerability towards viral infections in septic patients and open up new avenues to investigate therapeutic measures to prevent this. Furthermore, it provides important implications regarding the safety and efficacy of the vaccine in (post)septic or immunocompromised patients.

Objective: Our primary objective is to investigate the effects of endotoxin-induced systemic inflammation and subsequent development of endotoxin tolerance on the inflammatory response following Fluenz administration in vivo. To evaluate whether these effects involve local and/or systemic inflammation, symptoms, temperature and peak expiratory flow will be measured. Next, local inflammatory parameters are measured in nasal wash and systemic inflammatory parameters are measured in blood. Furthermore, we want to evaluate whether preceding endotoxemia influences the viral shedding of influenza in nasal wash. Also, changes in the mucosal microbiome, transcriptome and metabolome will be assessed. Finally, mitochondrial function and mental strength during human endotoxemia will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date February 2018
Est. primary completion date January 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Healthy

Exclusion Criteria:

- Pre-existent lung disease, including asthma, severe allergic rhinitis

- Use of any medication

- Current smoker or more than 5 pack-year history

- Use of recreational drugs within 21 days prior to start of the study

- Use of caffeine or alcohol within 1 day prior to start of the study

- Surgery or trauma with significant blood loss or blood donation within 3 months prior to start of the study

- Participation in another clinical trial within 3 months prior to start of the study

- Frequent nosebleeds

- Recent nasal or otologic surgery

- (suspected) influenza infection during the last year

- Clinically significant acute (febrile) illness or a common cold within four weeks prior to start of the study

- History of frequent vaso-vagal collapse or of orthostatic hypotension History, signs or symptoms of cardiovascular disease.

- History of allergic reaction to Fluenz™, eggs / gelatin / gentamicin

- History of Guillain-Barré Syndrome

- Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular block or a complex bundle branch block.

- Hypertension (defined as Blood pressure (RR) systolic > 160 or RR diastolic > 90).

- Hypotension (defined as RR systolic < 100 or RR diastolic < 50).

- Renal impairment (defined as plasma creatinin >120 µmol/l).

- Liver function abnormality: alkaline phosphatase>230 U/L and/or Alanine-aminotransferase (ALT)>90 units per Liter (U/L)

- C-reactive protein (CRP) > 20 mg/L, white blood cell count (WBC) > 12x109/L

- Vaccination with influenza this season

- Recent vaccination

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Fluenz
intranasal inoculation with Fluenz
Other:
placebo

LPS


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Radboud University

Outcome

Type Measure Description Time frame Safety issue
Primary Peak Levels of Interferon Gamma-induced Protein 10 (IP-10) in Nasal Wash Fluid Interferon gamma-induced protein 10 is a marker of viral-induced inflammation. Higher levels indicate a more pronounced inflammatory response upon a viral infection. 35 days after FLuenz inoculation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Recruiting NCT06243289 - Improving KIdney Transplantation With Cellular Therapy Study
Recruiting NCT03591302 - Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs. Phase 1
Completed NCT04525456 - Immune Responses With Reduxium N/A
Recruiting NCT04314518 - The Correlation Between Immunological Reaction of the Seminal Fluid in the Mother's Blood and Pregnancy Complications
Enrolling by invitation NCT04571203 - Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment Phase 1
Recruiting NCT01367821 - Immune Function in Patients With Obstructive Jaundice N/A
Enrolling by invitation NCT01117077 - The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis N/A
Terminated NCT05010174 - Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Active, not recruiting NCT03744325 - Immune Responses in Hen's Egg Oral Immunotherapy N/A
Completed NCT03383211 - Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Recruiting NCT02861872 - Intra-peritoneal Chemotherapy in Ovarian Cancer N/A
Active, not recruiting NCT00319657 - Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs Phase 1/Phase 2
Completed NCT01538485 - Vitamin D Supplementation and Regulatory FoxP3+ T Cells in the GUT Phase 4
Completed NCT03393793 - HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Completed NCT01996774 - Immunologic Profile of Children With Severe Allergies to Peanuts and Nuts After Induction of Tolerance N/A
Recruiting NCT03292445 - Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation Early Phase 1
Active, not recruiting NCT05745792 - Clinico-immunological Characterization and Immune Tolerance Breakdown in HU-autoimmunity
Completed NCT01414504 - Pneumococcal Conjugate Vaccine Followup Phase 2
Not yet recruiting NCT06147375 - Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation N/A